Open AccessDrug usage evaluation of dapsone
Author(s) -
G Kannan,
J Vasantha,
N Vanitha Rani,
P Thennarasu,
K Kousalya,
P Anuradha,
Chakradhar Reddy
Publication year - 2009
Publication title -
indian journal of pharmaceutical sciences/indian journal of pharmaceutical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.245
H-Index - 57
eISSN - 1998-3743
pISSN - 0250-474X
DOI - 10.4103/0250-474x.57301
Subject(s) - medicine , dapsone , leprosy , dermatology , adverse effect , dermatitis herpetiformis , drug , exfoliative dermatitis , population , rash , disease , pharmacology , environmental health
Dapsone has been the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. It is also widely used by dermatologists in varied skin conditions like dermatitis herpetiformis, bullous pemphigoid, Behcet's disease, lupus erythematous and a host of other skin diseases. Hence an attempt has been made to review the utilization and qualitative evaluation of dapsone over a period of 6 months in a tertiary care teaching hospital. The study consisted of 80 patients (54 leprosy and 26 non-leprosy patients), prescribed with dapsone 100 mg oral once daily. The prescribing patterns of dapsone in leprosy and other dermatological conditions (non-leprosy) were analyzed and the safety, efficacy and appropriateness of the doses prescribed were reviewed. The adverse drug reactions observed in the study population were type I Lepra reactions, gastrointestinal side effects (abdominal pain and anorexia), peripheral neuropathy, other nervous side effects (insomnia, headache and vertigo) and other adverse reactions (fever and tinnitus). Patient information leaflets were distributed to patients to educate on the appropriate use of dapsone.